| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Alzheimer Disease | 44 | 2023 | 2118 | 4.900 |
Why?
|
| Brain | 41 | 2023 | 1663 | 4.760 |
Why?
|
| Dementia | 20 | 2022 | 575 | 3.700 |
Why?
|
| Cognition Disorders | 28 | 2020 | 1003 | 3.630 |
Why?
|
| Diabetes Mellitus | 10 | 2023 | 137 | 3.520 |
Why?
|
| Diabetes Mellitus, Type 2 | 9 | 2020 | 191 | 2.780 |
Why?
|
| Cognition | 18 | 2024 | 1353 | 2.340 |
Why?
|
| Aged, 80 and over | 60 | 2022 | 4857 | 2.050 |
Why?
|
| Brain Infarction | 7 | 2021 | 75 | 2.040 |
Why?
|
| Insulin | 7 | 2023 | 90 | 1.980 |
Why?
|
| Cognitive Dysfunction | 9 | 2024 | 1065 | 1.920 |
Why?
|
| Insulin Resistance | 4 | 2023 | 52 | 1.770 |
Why?
|
| Cerebral Infarction | 7 | 2023 | 148 | 1.740 |
Why?
|
| Cerebrovascular Disorders | 4 | 2021 | 134 | 1.650 |
Why?
|
| Neuropsychological Tests | 32 | 2024 | 1226 | 1.620 |
Why?
|
| Aging | 23 | 2022 | 1550 | 1.620 |
Why?
|
| Humans | 98 | 2024 | 28386 | 1.580 |
Why?
|
| Antibodies, Antiphospholipid | 3 | 2019 | 23 | 1.500 |
Why?
|
| Neurofibrillary Tangles | 7 | 2018 | 193 | 1.480 |
Why?
|
| Aged | 59 | 2024 | 9278 | 1.480 |
Why?
|
| tau Proteins | 9 | 2021 | 235 | 1.450 |
Why?
|
| Blood Pressure | 5 | 2020 | 202 | 1.430 |
Why?
|
| Female | 73 | 2024 | 15704 | 1.380 |
Why?
|
| Male | 71 | 2022 | 15266 | 1.320 |
Why?
|
| Risk Factors | 23 | 2024 | 2398 | 1.160 |
Why?
|
| Memory Disorders | 5 | 2020 | 162 | 1.100 |
Why?
|
| Biomarkers | 5 | 2024 | 592 | 1.070 |
Why?
|
| Plaque, Amyloid | 6 | 2018 | 146 | 1.030 |
Why?
|
| Cohort Studies | 21 | 2022 | 1925 | 1.020 |
Why?
|
| Cardiovascular Diseases | 4 | 2024 | 372 | 1.020 |
Why?
|
| Apolipoprotein E4 | 9 | 2022 | 264 | 0.950 |
Why?
|
| Amyloid beta-Peptides | 5 | 2021 | 327 | 0.950 |
Why?
|
| Insulin-Like Growth Factor I | 2 | 2024 | 59 | 0.940 |
Why?
|
| Longitudinal Studies | 23 | 2020 | 1384 | 0.930 |
Why?
|
| Memory, Episodic | 2 | 2023 | 116 | 0.900 |
Why?
|
| Signal Transduction | 4 | 2021 | 447 | 0.870 |
Why?
|
| Metformin | 1 | 2023 | 20 | 0.860 |
Why?
|
| Neuroimaging | 4 | 2021 | 128 | 0.830 |
Why?
|
| Cell-Free Nucleic Acids | 1 | 2023 | 13 | 0.820 |
Why?
|
| Cerebral Amyloid Angiopathy | 6 | 2021 | 113 | 0.780 |
Why?
|
| Radar | 1 | 2022 | 6 | 0.780 |
Why?
|
| Diabetes Complications | 6 | 2021 | 59 | 0.740 |
Why?
|
| Cross-Sectional Studies | 8 | 2024 | 929 | 0.720 |
Why?
|
| Neuropathology | 2 | 2019 | 82 | 0.720 |
Why?
|
| Hypoglycemic Agents | 3 | 2019 | 40 | 0.700 |
Why?
|
| White Matter | 4 | 2019 | 134 | 0.700 |
Why?
|
| Body Mass Index | 3 | 2020 | 463 | 0.690 |
Why?
|
| Autopsy | 9 | 2021 | 343 | 0.680 |
Why?
|
| Hypertension | 2 | 2020 | 232 | 0.670 |
Why?
|
| Adipokines | 1 | 2019 | 7 | 0.660 |
Why?
|
| Drug Repositioning | 1 | 2019 | 5 | 0.650 |
Why?
|
| Cerebral Arteries | 3 | 2016 | 25 | 0.650 |
Why?
|
| Motor Disorders | 1 | 2019 | 23 | 0.620 |
Why?
|
| Insulin-Like Growth Factor Binding Protein 5 | 1 | 2019 | 26 | 0.620 |
Why?
|
| Parkinsonian Disorders | 5 | 2010 | 226 | 0.600 |
Why?
|
| Geriatric Assessment | 3 | 2016 | 211 | 0.580 |
Why?
|
| Depressive Disorder | 1 | 2019 | 186 | 0.570 |
Why?
|
| Gray Matter | 2 | 2015 | 51 | 0.570 |
Why?
|
| Follow-Up Studies | 9 | 2020 | 1859 | 0.510 |
Why?
|
| Heme Oxygenase-1 | 3 | 2014 | 7 | 0.440 |
Why?
|
| 5-Methylcytosine | 2 | 2023 | 6 | 0.420 |
Why?
|
| Intracranial Arteriosclerosis | 3 | 2021 | 53 | 0.410 |
Why?
|
| Epidemiologic Research Design | 1 | 2012 | 15 | 0.410 |
Why?
|
| Hypercholesterolemia | 2 | 2010 | 27 | 0.410 |
Why?
|
| Movement Disorders | 1 | 2012 | 90 | 0.380 |
Why?
|
| Mental Status Schedule | 5 | 2018 | 93 | 0.370 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 2 | 2010 | 61 | 0.360 |
Why?
|
| Middle Aged | 18 | 2024 | 9270 | 0.340 |
Why?
|
| Heptanoic Acids | 1 | 2010 | 5 | 0.340 |
Why?
|
| Age Factors | 5 | 2021 | 779 | 0.340 |
Why?
|
| Pyrroles | 1 | 2010 | 24 | 0.340 |
Why?
|
| Frontotemporal Dementia | 1 | 2010 | 13 | 0.330 |
Why?
|
| Vascular Diseases | 2 | 2021 | 44 | 0.330 |
Why?
|
| Memory | 5 | 2020 | 302 | 0.330 |
Why?
|
| Neurodegenerative Diseases | 2 | 2001 | 124 | 0.330 |
Why?
|
| Prospective Studies | 7 | 2020 | 1798 | 0.320 |
Why?
|
| Cerebral Cortex | 4 | 2022 | 161 | 0.310 |
Why?
|
| Apolipoproteins E | 5 | 2022 | 252 | 0.310 |
Why?
|
| Phospholipases A2, Cytosolic | 3 | 2022 | 6 | 0.290 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 2008 | 111 | 0.280 |
Why?
|
| Risk Assessment | 4 | 2022 | 674 | 0.280 |
Why?
|
| Asparagine | 1 | 2006 | 2 | 0.280 |
Why?
|
| Smoking | 3 | 2020 | 177 | 0.270 |
Why?
|
| Linear Models | 3 | 2020 | 251 | 0.270 |
Why?
|
| Lysine | 1 | 2006 | 15 | 0.270 |
Why?
|
| Logistic Models | 5 | 2017 | 396 | 0.270 |
Why?
|
| Gait Disorders, Neurologic | 2 | 2007 | 139 | 0.260 |
Why?
|
| Vascular Endothelial Growth Factor A | 2 | 2024 | 71 | 0.260 |
Why?
|
| Incidence | 5 | 2020 | 773 | 0.260 |
Why?
|
| Neuroglia | 2 | 2007 | 49 | 0.250 |
Why?
|
| Magnetic Resonance Imaging | 6 | 2015 | 1142 | 0.240 |
Why?
|
| Independent Living | 2 | 2018 | 318 | 0.240 |
Why?
|
| Gene Expression Regulation, Enzymologic | 1 | 2005 | 34 | 0.240 |
Why?
|
| Postmortem Changes | 3 | 2019 | 31 | 0.240 |
Why?
|
| Hospitalization | 2 | 2018 | 323 | 0.240 |
Why?
|
| Mutation | 1 | 2006 | 354 | 0.240 |
Why?
|
| Lewy Body Disease | 4 | 2012 | 100 | 0.240 |
Why?
|
| Diabetic Neuropathies | 1 | 2004 | 12 | 0.230 |
Why?
|
| Animals | 7 | 2022 | 3780 | 0.230 |
Why?
|
| Calcium | 3 | 2022 | 380 | 0.230 |
Why?
|
| Brain-Derived Neurotrophic Factor | 1 | 2024 | 48 | 0.220 |
Why?
|
| Neurons | 3 | 2022 | 342 | 0.210 |
Why?
|
| Insulin Receptor Substrate Proteins | 2 | 2014 | 15 | 0.210 |
Why?
|
| Biomedical Research | 1 | 2023 | 66 | 0.200 |
Why?
|
| Group IV Phospholipases A2 | 1 | 2022 | 6 | 0.200 |
Why?
|
| Creatinine | 1 | 2002 | 48 | 0.200 |
Why?
|
| Anniversaries and Special Events | 1 | 2021 | 3 | 0.190 |
Why?
|
| Inflammation | 3 | 2022 | 284 | 0.190 |
Why?
|
| Neuromuscular Diseases | 1 | 2001 | 5 | 0.190 |
Why?
|
| Hemoglobins | 1 | 2022 | 78 | 0.190 |
Why?
|
| DNA Methylation | 1 | 2023 | 165 | 0.180 |
Why?
|
| Amyloid beta-Protein Precursor | 1 | 2021 | 17 | 0.180 |
Why?
|
| MAP Kinase Signaling System | 1 | 2021 | 37 | 0.180 |
Why?
|
| Genetic Variation | 2 | 2016 | 97 | 0.180 |
Why?
|
| Child, Preschool | 1 | 2022 | 679 | 0.170 |
Why?
|
| Excitatory Amino Acid Antagonists | 1 | 2019 | 15 | 0.170 |
Why?
|
| Memantine | 1 | 2019 | 9 | 0.170 |
Why?
|
| Cholinesterase Inhibitors | 1 | 2019 | 15 | 0.170 |
Why?
|
| Cerebrovascular Circulation | 2 | 2019 | 34 | 0.160 |
Why?
|
| Leptin | 1 | 2019 | 22 | 0.160 |
Why?
|
| Mental Status and Dementia Tests | 1 | 2019 | 69 | 0.160 |
Why?
|
| Metabolic Syndrome | 1 | 2020 | 62 | 0.160 |
Why?
|
| Blood Pressure Determination | 1 | 2019 | 17 | 0.160 |
Why?
|
| HSP27 Heat-Shock Proteins | 1 | 2019 | 18 | 0.160 |
Why?
|
| Arteriolosclerosis | 2 | 2018 | 77 | 0.160 |
Why?
|
| Comorbidity | 4 | 2014 | 500 | 0.150 |
Why?
|
| Frontal Lobe | 1 | 1999 | 81 | 0.150 |
Why?
|
| Blood Glucose | 1 | 2019 | 108 | 0.150 |
Why?
|
| Temporal Lobe | 1 | 1999 | 84 | 0.150 |
Why?
|
| Central Nervous System Infections | 1 | 1998 | 4 | 0.150 |
Why?
|
| Mycobacterium tuberculosis | 1 | 1998 | 17 | 0.150 |
Why?
|
| Economics | 1 | 2018 | 17 | 0.150 |
Why?
|
| Community Health Planning | 1 | 2018 | 21 | 0.150 |
Why?
|
| Proteomics | 1 | 2019 | 93 | 0.150 |
Why?
|
| Tuberculosis | 1 | 1998 | 20 | 0.150 |
Why?
|
| Brain Diseases | 1 | 1999 | 67 | 0.150 |
Why?
|
| Mice | 5 | 2022 | 1461 | 0.150 |
Why?
|
| Mice, Transgenic | 4 | 2022 | 225 | 0.140 |
Why?
|
| Prefrontal Cortex | 1 | 2019 | 137 | 0.140 |
Why?
|
| Sex Characteristics | 1 | 2018 | 118 | 0.140 |
Why?
|
| Astrocytes | 2 | 2021 | 150 | 0.140 |
Why?
|
| Lewy Bodies | 3 | 2015 | 194 | 0.140 |
Why?
|
| Ambulatory Care | 1 | 2017 | 74 | 0.140 |
Why?
|
| Health Literacy | 1 | 2018 | 109 | 0.130 |
Why?
|
| Religious Personnel | 1 | 2016 | 11 | 0.130 |
Why?
|
| PubMed | 1 | 2016 | 10 | 0.130 |
Why?
|
| Arterioles | 1 | 2016 | 12 | 0.130 |
Why?
|
| Organ Specificity | 1 | 2016 | 43 | 0.130 |
Why?
|
| Nerve Degeneration | 2 | 2014 | 49 | 0.130 |
Why?
|
| Depression | 1 | 2020 | 452 | 0.130 |
Why?
|
| Reactive Oxygen Species | 3 | 2022 | 119 | 0.120 |
Why?
|
| Chromosomes, Human, Pair 17 | 2 | 2006 | 7 | 0.120 |
Why?
|
| Chronic Disease | 1 | 2017 | 440 | 0.120 |
Why?
|
| Diagnosis, Differential | 2 | 2010 | 371 | 0.120 |
Why?
|
| beta 2-Glycoprotein I | 1 | 2014 | 7 | 0.120 |
Why?
|
| Phosphatidylserines | 1 | 2014 | 7 | 0.120 |
Why?
|
| Lupus Coagulation Inhibitor | 1 | 2014 | 7 | 0.120 |
Why?
|
| Motor Skills | 1 | 2015 | 52 | 0.120 |
Why?
|
| Autoantigens | 1 | 2014 | 25 | 0.120 |
Why?
|
| Serine | 1 | 2014 | 10 | 0.120 |
Why?
|
| Microglia | 1 | 2016 | 145 | 0.120 |
Why?
|
| Residence Characteristics | 1 | 2016 | 215 | 0.120 |
Why?
|
| Single-Blind Method | 1 | 2014 | 110 | 0.120 |
Why?
|
| Tauopathies | 1 | 2014 | 21 | 0.110 |
Why?
|
| Randomized Controlled Trials as Topic | 2 | 2020 | 330 | 0.110 |
Why?
|
| Inclusion Bodies | 1 | 2014 | 13 | 0.110 |
Why?
|
| Neoplasms | 1 | 2017 | 238 | 0.110 |
Why?
|
| Membrane Proteins | 1 | 2014 | 171 | 0.100 |
Why?
|
| Atrophy | 3 | 2005 | 93 | 0.100 |
Why?
|
| Supranuclear Palsy, Progressive | 2 | 2003 | 28 | 0.100 |
Why?
|
| Hallucinations | 1 | 2012 | 64 | 0.100 |
Why?
|
| Motor Activity | 1 | 2015 | 329 | 0.100 |
Why?
|
| Immunohistochemistry | 2 | 2021 | 362 | 0.100 |
Why?
|
| Phosphorylation | 3 | 2021 | 149 | 0.100 |
Why?
|
| Leukotriene B4 | 2 | 2022 | 5 | 0.100 |
Why?
|
| Synaptosomes | 2 | 2022 | 8 | 0.100 |
Why?
|
| Apolipoprotein E3 | 2 | 2022 | 16 | 0.100 |
Why?
|
| Peptide Fragments | 2 | 2021 | 77 | 0.090 |
Why?
|
| Statistics as Topic | 3 | 2007 | 107 | 0.090 |
Why?
|
| United States | 6 | 2020 | 2200 | 0.090 |
Why?
|
| Disease Progression | 3 | 2016 | 714 | 0.090 |
Why?
|
| Oxidative Stress | 2 | 2022 | 107 | 0.090 |
Why?
|
| Severity of Illness Index | 2 | 2015 | 988 | 0.090 |
Why?
|
| Microcirculation | 1 | 2011 | 29 | 0.090 |
Why?
|
| Heterozygote | 3 | 2021 | 102 | 0.090 |
Why?
|
| Chicago | 3 | 2020 | 947 | 0.090 |
Why?
|
| Research Design | 1 | 2012 | 207 | 0.090 |
Why?
|
| Amyloid | 1 | 2010 | 56 | 0.090 |
Why?
|
| Hippocampus | 3 | 2022 | 278 | 0.090 |
Why?
|
| Adult | 5 | 2020 | 8098 | 0.080 |
Why?
|
| Dementia, Vascular | 2 | 2007 | 45 | 0.080 |
Why?
|
| Clergy | 3 | 2006 | 92 | 0.080 |
Why?
|
| Terminology as Topic | 1 | 2010 | 32 | 0.080 |
Why?
|
| Sterols | 1 | 2009 | 5 | 0.080 |
Why?
|
| Family Health | 2 | 2006 | 36 | 0.080 |
Why?
|
| Public Health | 1 | 2010 | 70 | 0.080 |
Why?
|
| Postural Balance | 2 | 2007 | 122 | 0.080 |
Why?
|
| Glial Fibrillary Acidic Protein | 2 | 2007 | 42 | 0.080 |
Why?
|
| Regression Analysis | 3 | 2021 | 265 | 0.080 |
Why?
|
| Accidental Falls | 1 | 2010 | 114 | 0.080 |
Why?
|
| Intracranial Hemorrhages | 1 | 2008 | 13 | 0.070 |
Why?
|
| Isometric Contraction | 1 | 2007 | 13 | 0.070 |
Why?
|
| Housing for the Elderly | 1 | 2007 | 8 | 0.070 |
Why?
|
| Receptors, Erythropoietin | 1 | 2007 | 2 | 0.070 |
Why?
|
| Protein Processing, Post-Translational | 2 | 2021 | 39 | 0.070 |
Why?
|
| Neuroprotective Agents | 1 | 2008 | 55 | 0.070 |
Why?
|
| Lower Extremity | 1 | 2007 | 39 | 0.070 |
Why?
|
| Fluorodeoxyglucose F18 | 1 | 2006 | 37 | 0.070 |
Why?
|
| Positron-Emission Tomography | 1 | 2006 | 89 | 0.070 |
Why?
|
| Decision Support Techniques | 1 | 2006 | 52 | 0.070 |
Why?
|
| Gait | 2 | 2007 | 413 | 0.070 |
Why?
|
| Muscle Strength | 1 | 2007 | 136 | 0.070 |
Why?
|
| Spatial Behavior | 1 | 2006 | 9 | 0.060 |
Why?
|
| Enzyme Activation | 2 | 2021 | 120 | 0.060 |
Why?
|
| Parkinson Disease | 3 | 2005 | 859 | 0.060 |
Why?
|
| Leg | 1 | 2006 | 52 | 0.060 |
Why?
|
| Visual Acuity | 1 | 2006 | 39 | 0.060 |
Why?
|
| Cell Count | 1 | 2005 | 79 | 0.060 |
Why?
|
| Causality | 2 | 2020 | 56 | 0.060 |
Why?
|
| alpha-Synuclein | 2 | 2018 | 133 | 0.060 |
Why?
|
| Heart Failure | 1 | 2007 | 179 | 0.060 |
Why?
|
| DNA-Binding Proteins | 2 | 2018 | 274 | 0.060 |
Why?
|
| Muscle Rigidity | 1 | 2004 | 21 | 0.060 |
Why?
|
| Hypokinesia | 1 | 2004 | 23 | 0.060 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2006 | 390 | 0.060 |
Why?
|
| Alleles | 2 | 2015 | 221 | 0.050 |
Why?
|
| Cytosine | 1 | 2023 | 5 | 0.050 |
Why?
|
| Point Mutation | 1 | 2003 | 27 | 0.050 |
Why?
|
| Tremor | 1 | 2004 | 117 | 0.050 |
Why?
|
| Eicosapentaenoic Acid | 1 | 2022 | 9 | 0.050 |
Why?
|
| Arachidonate 5-Lipoxygenase | 1 | 2022 | 6 | 0.050 |
Why?
|
| Epoxide Hydrolases | 1 | 2022 | 11 | 0.050 |
Why?
|
| Odds Ratio | 2 | 2017 | 268 | 0.050 |
Why?
|
| Carnitine | 1 | 2022 | 8 | 0.050 |
Why?
|
| Chromatography, Liquid | 1 | 2022 | 23 | 0.050 |
Why?
|
| Tandem Mass Spectrometry | 1 | 2022 | 21 | 0.050 |
Why?
|
| Kidney Function Tests | 1 | 2002 | 21 | 0.050 |
Why?
|
| Fatty Acids | 1 | 2022 | 41 | 0.050 |
Why?
|
| Hypoxia | 1 | 2022 | 36 | 0.050 |
Why?
|
| Socioeconomic Factors | 2 | 2018 | 310 | 0.050 |
Why?
|
| Reference Values | 1 | 2002 | 194 | 0.050 |
Why?
|
| Databases, Factual | 1 | 2023 | 358 | 0.050 |
Why?
|
| Tomography, Emission-Computed | 1 | 2001 | 9 | 0.050 |
Why?
|
| Aphasia, Primary Progressive | 1 | 2001 | 2 | 0.050 |
Why?
|
| Spinocerebellar Degenerations | 1 | 2001 | 4 | 0.050 |
Why?
|
| p38 Mitogen-Activated Protein Kinases | 1 | 2021 | 36 | 0.050 |
Why?
|
| Fatal Outcome | 1 | 2001 | 57 | 0.050 |
Why?
|
| Arteriosclerosis | 1 | 2021 | 13 | 0.050 |
Why?
|
| Inflammasomes | 1 | 2021 | 17 | 0.050 |
Why?
|
| Stroke | 1 | 2004 | 276 | 0.050 |
Why?
|
| NF-kappa B | 1 | 2021 | 118 | 0.040 |
Why?
|
| Genotype | 2 | 2015 | 359 | 0.040 |
Why?
|
| AIDS Dementia Complex | 1 | 2000 | 40 | 0.040 |
Why?
|
| Life Style | 1 | 2020 | 200 | 0.040 |
Why?
|
| National Institute on Aging (U.S.) | 1 | 2019 | 17 | 0.040 |
Why?
|
| Self Report | 1 | 2020 | 221 | 0.040 |
Why?
|
| Obesity | 1 | 2021 | 320 | 0.040 |
Why?
|
| Blood-Brain Barrier | 1 | 2019 | 39 | 0.040 |
Why?
|
| Polymorphism, Restriction Fragment Length | 1 | 1998 | 7 | 0.040 |
Why?
|
| DNA Fingerprinting | 1 | 1998 | 6 | 0.040 |
Why?
|
| Antitubercular Agents | 1 | 1998 | 12 | 0.040 |
Why?
|
| Meningitis | 1 | 1998 | 8 | 0.040 |
Why?
|
| Analysis of Variance | 2 | 2014 | 269 | 0.040 |
Why?
|
| Species Specificity | 1 | 1998 | 42 | 0.040 |
Why?
|
| Chi-Square Distribution | 1 | 2018 | 146 | 0.040 |
Why?
|
| Canada | 1 | 1998 | 51 | 0.040 |
Why?
|
| Prognosis | 1 | 2020 | 825 | 0.030 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2001 | 730 | 0.030 |
Why?
|
| Likelihood Functions | 1 | 2017 | 27 | 0.030 |
Why?
|
| Brazil | 1 | 2017 | 41 | 0.030 |
Why?
|
| Exercise | 1 | 2020 | 473 | 0.030 |
Why?
|
| Neurologic Examination | 2 | 2007 | 114 | 0.030 |
Why?
|
| Arterial Pressure | 1 | 2016 | 13 | 0.030 |
Why?
|
| Multivariate Analysis | 1 | 2017 | 331 | 0.030 |
Why?
|
| Diagnosis | 1 | 2015 | 24 | 0.030 |
Why?
|
| Educational Status | 1 | 2017 | 300 | 0.030 |
Why?
|
| Genetic Association Studies | 1 | 2015 | 85 | 0.030 |
Why?
|
| Healthy Volunteers | 1 | 2015 | 41 | 0.030 |
Why?
|
| Actigraphy | 1 | 2015 | 99 | 0.030 |
Why?
|
| Diet, High-Fat | 1 | 2014 | 16 | 0.030 |
Why?
|
| Psychiatric Status Rating Scales | 1 | 2015 | 326 | 0.030 |
Why?
|
| Green Fluorescent Proteins | 1 | 2014 | 23 | 0.030 |
Why?
|
| Animals, Newborn | 1 | 2014 | 45 | 0.030 |
Why?
|
| Glycoproteins | 1 | 2014 | 46 | 0.030 |
Why?
|
| Magnetic Resonance Spectroscopy | 1 | 2013 | 41 | 0.030 |
Why?
|
| Case-Control Studies | 1 | 2015 | 594 | 0.030 |
Why?
|
| Delusions | 1 | 2012 | 10 | 0.030 |
Why?
|
| Mice, Inbred C57BL | 1 | 2014 | 435 | 0.030 |
Why?
|
| TDP-43 Proteinopathies | 1 | 2014 | 110 | 0.030 |
Why?
|
| Image Processing, Computer-Assisted | 1 | 2013 | 169 | 0.030 |
Why?
|
| Age of Onset | 1 | 2012 | 99 | 0.030 |
Why?
|
| Epidemiologic Studies | 1 | 2012 | 24 | 0.030 |
Why?
|
| Phosphoserine | 1 | 2012 | 5 | 0.020 |
Why?
|
| Cerebellar Cortex | 1 | 2012 | 7 | 0.020 |
Why?
|
| Time Factors | 1 | 2016 | 1491 | 0.020 |
Why?
|
| Drug Resistance | 1 | 2012 | 47 | 0.020 |
Why?
|
| Rats | 1 | 2014 | 678 | 0.020 |
Why?
|
| Glucose | 1 | 2012 | 55 | 0.020 |
Why?
|
| Treatment Outcome | 1 | 2020 | 3612 | 0.020 |
Why?
|
| Recombinant Proteins | 1 | 2012 | 213 | 0.020 |
Why?
|
| Gas Chromatography-Mass Spectrometry | 1 | 2009 | 13 | 0.020 |
Why?
|
| Neocortex | 1 | 2009 | 31 | 0.020 |
Why?
|
| Models, Neurological | 1 | 2009 | 25 | 0.020 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2009 | 98 | 0.020 |
Why?
|
| Cholesterol | 1 | 2009 | 64 | 0.020 |
Why?
|
| Up-Regulation | 1 | 2009 | 178 | 0.020 |
Why?
|
| Peripheral Nervous System Diseases | 1 | 2007 | 29 | 0.020 |
Why?
|
| Long-Term Care | 1 | 2007 | 58 | 0.020 |
Why?
|
| Florida | 1 | 2006 | 22 | 0.020 |
Why?
|
| Pedigree | 1 | 2006 | 67 | 0.020 |
Why?
|
| Ambulatory Care Facilities | 1 | 2006 | 40 | 0.020 |
Why?
|
| Bias | 1 | 2006 | 41 | 0.020 |
Why?
|
| Community Health Services | 1 | 2006 | 35 | 0.020 |
Why?
|
| Mobility Limitation | 1 | 2006 | 94 | 0.020 |
Why?
|
| Brain Chemistry | 1 | 2005 | 44 | 0.020 |
Why?
|
| Syndrome | 1 | 2005 | 80 | 0.020 |
Why?
|
| Gene Expression Regulation | 1 | 2007 | 281 | 0.020 |
Why?
|
| Disability Evaluation | 1 | 2007 | 289 | 0.020 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2006 | 122 | 0.020 |
Why?
|
| Observer Variation | 1 | 2005 | 102 | 0.020 |
Why?
|
| Family | 1 | 2006 | 115 | 0.010 |
Why?
|
| Predictive Value of Tests | 1 | 2006 | 490 | 0.010 |
Why?
|
| Antihypertensive Agents | 1 | 2005 | 76 | 0.010 |
Why?
|
| Sensitivity and Specificity | 1 | 2006 | 518 | 0.010 |
Why?
|
| Prevalence | 1 | 2006 | 467 | 0.010 |
Why?
|
| Proportional Hazards Models | 1 | 2005 | 352 | 0.010 |
Why?
|
| Practice Guidelines as Topic | 1 | 2006 | 320 | 0.010 |
Why?
|
| Reproducibility of Results | 1 | 2006 | 737 | 0.010 |
Why?
|
| Activities of Daily Living | 1 | 2007 | 608 | 0.010 |
Why?
|
| Retrospective Studies | 1 | 2005 | 3611 | 0.010 |
Why?
|